Scale-Up of an Human Papillomavirus Testing Implementation Program in El Salvador
Morales Velado, Mario
Castle, Philip E.
Gage, Julia C.
MetadataShow full item record
CitationCremer, Miriam, Mauricio Maza, Karla Alfaro, Mario Morales Velado, Juan Felix, Philip E. Castle, Jane Kim, and Julia C. Gage. 2016. “Scale-Up of an Human Papillomavirus Testing Implementation Program in El Salvador.” Journal of Lower Genital Tract Disease 21 (1): 26-32. doi:10.1097/LGT.0000000000000280. http://dx.doi.org/10.1097/LGT.0000000000000280.
AbstractObjective: The Cervical Cancer Prevention in El Salvador is a demonstration project to introduce a lower-cost human papillomavirus (HPV)-DNA test into a public sector project. Started in October 2012, The Cervical Cancer Prevention in El Salvador consists of 3 phases and will ultimately screen 30,000 women. Results of phase 2 of the project are presented. The objective of this project was to compare colposcopy and noncolposcopy-based management for HPV-positive women. Material and Methods In phase 2, a total of 8,050 women, aged 30 to 49 years, were screened; 6,761 provided both self- and provider-collected specimens and 1,289 provided only provider-testing specimens. HPV results from self-collected specimens were not used in clinical management decisions. Women with provider-collected HPV-positive results were treated based on the strategy assigned to their community; the strategy was colposcopy management (CM) or screen-and-treat (ST) management if they were cryotherapy eligible or colposcopy if not eligible. Outcomes were assessed 6 months after screening. Results: Overall, 489 (12.3%) of 3,963 women receiving CM and 465 (11.4%) of 4,087 women receiving ST tested HPV positive. In the CM cohort, 216 (44.2%) of 489 completed their intervention (203 treated, 11 diagnosed negative, 2 pregnant). In the ST cohort, 411 (88.4%) of 465 completed their intervention (407 treated, 2 diagnosed negative, 1 pregnant). Overall agreement between HPV test results from self-collected and provider-collected specimens was 93.7%, with a κ value of 0.70 (95% CI = 0.68–0.73). Conclusions: Human papillomavirus testing with ST management resulted in an approximately twice completion rate compared with CM management. Agreement between self- and provider-based sampling was good and might be used to extend screening to women in areas that are more difficult to reach.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:30371132
- SPH Scholarly Articles